BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 22, 2013
View Archived Issues
Uncovering purinergic signaling as a potential drug target for autism spectrum disorders
Read More
New panels for prostate cancer diagnosis described
Read More
Johnson & Johnson reports achievements of first quarter 2013
Read More
GlaxoSmithKline presents novel PI3Kdelta inhibitors for treatment of respiratory diseases
Read More
NKTR-214 is significantly more efficacious in vivo compared to aldesleukin
Read More
CA6 is a potential novel gene biomarker for atopic dermatitis
Read More
Novel TYK2 inhibitors presented by Roche
Read More
Roche patents new CYP11B2 inhibitors
Read More
Novel tyrosine kinase inhibitors designed at Cellzome
Read More
Novel pan-pim inhibitor limits multiple myeloma tumor growth in vivo
Read More
Meiji Seika Pharma begins clinical testing of novel antifungal agent
Read More
Cipla launches biosimilar of etanercept in India
Read More
Afraxis identifies new PAK inhibitors
Read More
Novel EGFR inhibitors designed at Pfizer
Read More
Improvements in lung function observed in study of VX-661 and ivacaftor
Read More
Novel IRAK-4 inhibitors prepared at Aurigene Discovery
Read More
Pieris achieves second milestone under Anticalin collaboration
Read More
Lundbeck launches Selincro in European markets
Read More
Elan rejects Royalty Pharma's acquisition offer
Read More
Cerecor acquires rights to MK-0657 from Merck & Co.
Read More
Ceregene announces findings from phase IIb gene therapy study for Parkinson's disease
Read More
Phase II study of BI-505 in multiple myeloma begins
Read More
TiGenix reports phase IIa study results for Cx-611
Read More
BIND Therapeutics and AstraZeneca collaborate on cancer nanomedicine
Read More
FDA designates LJPC-6417 as an orphan drug product
Read More